Development of subtype-selective oestrogen receptor-based therapeutics

Nature Reviews Drug Discovery

Volumn 10, Issue 10, 2011, Pages 778-792

  Nilsson, Stefan ^a,b   Koehler, Konrad F ^a   Gustafsson, Jan Åke ^a,b,c  

^a Karo Bio   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c University of Houston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3,5 TRIS(4 HYDROXYPHENYL) 4 PROPYLPYRAZOLE; ANDROSTENEDIOL; CAVEOLIN 1; CHAPERONE; CHLOROINDAZOLE; DIARYLPROPIONITRILE; DIETHYLSTILBESTROL; ERB 196; ERTEBEREL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FOCAL ADHESION KINASE; GENISTEIN; HEAT SHOCK PROTEIN; INTERLEUKIN 10; INTERLEUKIN 4; LIQUIRITIGENIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PRINABEREL; RANTES; RECEPTOR INTERACTING PROTEIN 140; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; WO 01064665; WO 01072713; WO 04026290;

ALLERGIC ENCEPHALOMYELITIS; ALZHEIMER DISEASE; BINDING AFFINITY; BINDING SITE; BREAST CANCER; CALCIUM CELL LEVEL; CANCER GROWTH; CANCER RISK; CANCER THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL ACTIVITY; CELL INTERACTION; CELL MEMBRANE; CELL MOTILITY; CELL PROLIFERATION; COLON CANCER; CONFORMATIONAL TRANSITION; DISEASE COURSE; DISEASE MODEL; DRUG MECHANISM; DRUG SELECTIVITY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE TARGETING; GENETIC ASSOCIATION; HOMEOSTASIS; HORMONE ACTION; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LIGAND BINDING; MESOTHELIOMA; MULTIPLE SCLEROSIS; NONHUMAN; OSTEOPOROSIS; PHARMACOPHORE; POTASSIUM CURRENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REGULATORY MECHANISM; REVIEW; RISK REDUCTION; STRUCTURE ACTIVITY RELATION; T CELL LYMPHOMA; TRANSCRIPTION INITIATION; TREATMENT DURATION;

ALZHEIMER DISEASE; ANIMALS; BREAST NEOPLASMS; DRUG DISCOVERY; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SIGNAL TRANSDUCTION;

EID: 80053562371     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3551     Document Type: Review

References (139)

1. Boon, W. C., Chow, J. D. & Simpson, E. R. The multiple roles of estrogens and the enzyme aromatase. Prog. Brain Res. 181, 209-232 (2010).
2. Drummond, A. E. & Fuller, P. J. The importance of ERβ signalling in the ovary. J. Endocrinol. 205, 15-23 (2010).
3. Taylor, A. H. & Al-Azzawi, F. Immunolocalisation of oestrogen receptor β in human tissues. J. Mol. Endocrinol. 24, 145-155 (2000). (Pubitemid 30117668)
4. Saji, S. et al. Estrogen receptors α and β in the rodent mammary gland. Proc. Natl Acad. Sci. USA 97, 337-342 (2000). (Pubitemid 30055832)
5. Rody, A. et al. Methylation of estrogen receptor β promoter correlates with loss of ER-β expression in mammary carcinoma and is an early indication marker in premalignant lesions. Endocr. Relat. Cancer 12, 903-916 (2005). (Pubitemid 41815784)
6. Yang, X., Li, Y. Z., Mao, Z., Gu, P. & Shang, M. Effects of estrogen and tibolone on bladder histology and estrogen receptors in rats. Chin. Med. J. 122, 381-385 (2009).
7. Gorres, B. K., Bomhoff, G. L., Gupte, A. A. & Geiger, P. C. Altered estrogen receptor expression in skeletal muscle and adipose tissue of female rats fed a high-fat diet. J. Appl. Physiol. 110, 1046-1053 (2011).
8. Mitterling, K. L. et al. Cellular and subcellular localization of estrogen and progestin receptor immunoreactivities in the mouse hippocampus. J. Comp. Neurol. 518, 2729-2743 (2010).
9. Waters, E. M. et al. Estrogen and aging affect the synaptic distribution of estrogen receptor β-immunoreactivity in the CA1 region of female rat hippocampus. Brain Res. 1379, 86-97 (2011).
10. Rossouw, J. E. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288, 321-333 (2002). (Pubitemid 34761611)
11. Clarkson, T. B. & Appt, S. E. Controversies about HRT-lessons from monkey models. Maturitas 51, 64-74 (2005).
12. Harman, S. M. et al. Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes. Am. J. Med. 124, 199-205 (2011).
13. Mendelsohn, M. E. Estrogen actions in the cardiovascular system. Climacteric 12 (Suppl. 1), 18-21 (2009).
14. Tsai, S. A., Stefanick, M. L. & Stafford, R. S. Trends in menopausal hormone therapy use of US office-based physicians, 2000-2009. Menopause 18, 385-392 (2011).
15. Santen, R. J. et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J. Clin. Endocrinol. Metab. 95, S1-S66 (2010).
16. Leitman, D. C. et al. Regulation of specific target genes and biological responses by estrogen receptor subtype agonists. Curr. Opin. Pharmacol. 10, 629-636 (2010).
17. Frasor, J. et al. Response-specific and ligand dose-dependent modulation of estrogen receptor (ER) α activity by ERβ in the uterus. Endocrinology 144, 3159-3166 (2003). (Pubitemid 36819918)
18. Helguero, L. A., Faulds, M. H., Gustafsson, J.-Å. & Haldosen, L. A. Estrogen receptors alfa (ERα) and β (ERβ) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene 24, 6605-6616 (2005). (Pubitemid 41486791)
19. Gronemeyer, H., Gustafsson, J., & Laudet, V. Principles for modulation of the nuclear receptor superfamily. Nature Rev. Drug Discov. 3, 950-964 (2004). (Pubitemid 39534319)
20. Nilsson, S. & Gustafsson, J., in Nuclear Receptors: Current Concepts and Future Challenges (Proteins and Cell Regulation) (eds Bunce, C. M. & Campbell, M. J.) 91-141 (Springer, 2010).
21. Powell, E., Wang, Y., Shapiro, D. J. & Xu, W. Differential requirements of Hsp90 and DNA for the formation of estrogen receptor homodimers and heterodimers. J. Biol. Chem. 285, 16125-16134 (2010).
22. Safe, S. & Kim, K. Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways. J. Mol. Endocrinol. 41, 263-275 (2008).
23. Hall, J. M. & McDonnell, D. P. Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. Mol. Interv. 5, 343-357 (2005). (Pubitemid 43060715)
24. Shang, Y., Hu, X., DiRenzo, J., Lazar, M. A. & Brown, M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103, 843-852 (2000).
25. Powell, E. & Xu, W. Intermolecular interactions identify ligand-selective activity of estrogen receptor α/β dimers. Proc. Natl Acad. Sci. USA 105, 19012-19017 (2008).
26. Monroe, D. G. et al. Estrogen receptor α and β heterodimers exert unique effects on estrogen-and tamoxifen-dependent gene expression in human U2OS osteosarcoma cells. Mol. Endocrinol. 19, 1555-1568 (2005). (Pubitemid 41002985)
27. Charn, T. H. et al. Genome-wide dynamics of chromatin binding of estrogen receptors α and β: mutual restriction and competitive site selection. Mol. Endocrinol. 24, 47-59 (2010).
28. Perissi, V. & Rosenfeld, M. G. Controlling nuclear receptors: the circular logic of cofactor cycles. Nature Rev. Mol. Cell Biol. 6, 542-554 (2005). (Pubitemid 40943045)
29. Bramlett, K. S., Wu, Y. & Burris, T. P. Ligands specify coactivator nuclear receptor (NR) box affinity for estrogen receptor subtypes. Mol. Endocrinol. 15, 909-922 (2001). (Pubitemid 32510638)
30. Gee, A. C., Carlson, K. E., Martini, P. G., Katzenellenbogen, B. S. & Katzenellenbogen, J. A. Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor. Mol. Endocrinol. 13, 1912-1923 (1999). (Pubitemid 30645264)
31. Saijo, K., Collier, J. G., Li, A. C., Katzenellenbogen, J. A. & Glass, C. K. An ADIOL-ERβ-CtBP transrepression pathway negatively regulates microglia-mediated inflammation. Cell 145, 584-595 (2011).
32. Arpino, G., Wiechmann, L., Osborne, C. K. & Schiff, R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr. Rev. 29, 217-233 (2008). (Pubitemid 351519691)
33. Hammes, S. R. & Levin, E. R. Extranuclear steroid receptors: nature and actions. Endocr. Rev. 28, 726-741 (2007). (Pubitemid 350294293)
34. Acconcia, F., Ascenzi, P., Fabozzi, G., Visca, P. & Marino, M. S-palmitoylation modulates human estrogen receptor-α functions. Biochem. Biophys. Res. Commun. 316, 878-883 (2004). (Pubitemid 38372163)
35. Lu, Q. et al. Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthase by estrogen receptor α. Proc. Natl Acad. Sci. USA 101, 17126-17131 (2004). (Pubitemid 39627785)
36. Chambliss, K. L. et al. Non-nuclear estrogen receptor α signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. J. Clin. Invest. 120, 2319-2330 (2010).
37. Wu, Q., Chambliss, K., Umetani, M., Mineo, C. & Shaul, P. W. Non-nuclear estrogen receptor signaling in endothelium. J. Biol. Chem. 286, 14737-14743 (2011).
38. Le Romancer, M., Treilleux, I., Bouchekioua-Bouzaghou, K., Sentis, S. & Corbo, L. Methylation, a key step for nongenomic estrogen signaling in breast tumors. Steroids 75, 560-564 (2010).
39. Madak-Erdogan, Z. et al. Nuclear and extranuclear pathway inputs in the regulation of global gene expression by estrogen receptors. Mol. Endocrinol. 22, 2116-2127 (2008).
40. Harrington, W. R. et al. Estrogen dendrimer conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of estrogen action. Mol. Endocrinol. 20, 491-502 (2006). (Pubitemid 43291204)
41. Amazit, L. et al. Regulation of SRC-3 intercompartmental dynamics by estrogen receptor and phosphorylation. Mol. Cell. Biol. 27, 6913-6932 (2007). (Pubitemid 47483640)
42. Turjanski, A. G., Vaque, J. P. & Gutkind, J. S. MAP kinases and the control of nuclear events. Oncogene 26, 3240-3253 (2007). (Pubitemid 46763018)
43. Zhang, L. et al. Estrogen receptor β-selective agonists stimulate calcium oscillations in human and mouse embryonic stem cell-derived neurons. PLoS ONE 5, e11791 (2010).
44. Zhao, L. & Brinton, R. D. Estrogen receptor α and β differentially regulate intracellular Ca2+ dynamics leading to ERK phosphorylation and estrogen neuroprotection in hippocampal neurons. Brain Res. 1172, 48-59 (2007). (Pubitemid 47417943)
45. Anstead, G. M., Carlson, K. E. & Katzenellenbogen, J. A. The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids 62, 268-303 (1997). (Pubitemid 27114399)
46. Brzozowski, A. M. et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389, 753-758 (1997). (Pubitemid 27458965)
47. Minutolo, F., Macchia, M., Katzenellenbogen, B. S. & Katzenellenbogen, J. A. Estrogen receptor β ligands: recent advances and biomedical applications. Med. Res. Rev. 31, 364-442 (2011). A thorough review of the known chemical classes of ERβ-selective ligands, their pharmacophores and their potential therapeutic applications.
48. Mohler, M. L. et al. Estrogen receptor β selective nonsteroidal estrogens: seeking clinical indications. Expert Opin. Ther. Pat. 20, 507-534 (2010).
49. Kuiper, G. G. et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138, 863-870 (1997). (Pubitemid 27089735)
50. Meyers, M. J. et al. Estrogen receptor-β potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J. Med. Chem. 44, 4230-4251 (2001). (Pubitemid 33095330)
51. Bruning, J. B. et al. Coupling of receptor conformation and ligand orientation determine graded activity. Nature Chem. Biol. 6, 837-843 (2010).
52. Paruthiyil, S. et al. Drug and cell type-specific regulation of genes with different classes of estrogen receptor β-selective agonists. PLoS ONE 4, e6271 (2009).
53. Gellman, S. H. On the role of methionine residues in the sequence-independent recognition of nonpolar protein surfaces. Biochemistry 30, 6633-6636 (1991).
54. Manas, E. S., Xu, Z. B., Unwalla, R. J. & Somers, W. S. Understanding the selectivity of genistein for human estrogen receptor-β using X-ray crystallography and computational methods. Structure 12, 2197-2207 (2004). (Pubitemid 39610434)
55. Pike, A. C. et al. Structure of the ligand-binding domain of oestrogen receptor β in the presence of a partial agonist and a full antagonist. EMBO J. 18, 4608-4618 (1999). (Pubitemid 29415516)
56. Yu, H., Noskov, S. Y. & Roux, B. Two mechanisms of ion selectivity in protein binding sites. Proc. Natl Acad. Sci. USA 107, 20329-20334 (2010).
57. Hegele-Hartung, C. et al. Impact of isotype-selective estrogen receptor agonists on ovarian function. Proc. Natl Acad. Sci. USA 101, 5129-5134 (2004). (Pubitemid 38476910)
58. Blizzard, T. A. Selective estrogen receptor modulator medicinal chemistry at Merck. A review. Curr. Top. Med. Chem. 8, 792-812 (2008). (Pubitemid 351982567)
59. Richardson, T. I. et al. Benzopyrans as selective estrogen receptor β agonists (SERBAs). Part 5: combined A-and C-ring structure-activity relationship studies. Bioorg. Med. Chem. Lett. 17, 5563-5566 (2007). (Pubitemid 47391324)
60. Veeneman, G. H. & Teerhuis, N. M. Chroman derivatives as estrogenic compounds. US patent 0069303 (2003).
61. Ferriz, J. M. & Vinsova, J. Prodrug design of phenolic drugs. Curr. Pharm. Des. 16, 2033-2052 (2010).
62. Wilkening, R. R. et al. Estrogen receptor β-subtype selective tetrahydrofluorenones: use of a fused pyrazole as a phenol bioisostere. Bioorg. Med. Chem. Lett. 16, 3896-3901 (2006). (Pubitemid 43922414)
63. Gruvberger-Saal, S. K. et al. Estrogen receptor β expression is associated with tamoxifen response in ERα-negative breast carcinoma. Clin. Cancer Res. 13, 1987-1994 (2007). (Pubitemid 46649864)
64. Hartman, J., Strom, A. & Gustafsson, J. Estrogen receptor β in breast cancer-diagnostic and therapeutic implications. Steroids 74, 635-641 (2009).
65. Honma, N. et al. Clinical importance of estrogen receptor-β evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J. Clin. Oncol. 26, 3727-3734 (2008).
66. Wu, X. et al. Estrogen receptor-β sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen. Breast Cancer Res. 13, R27 (2011).
67. Chang, E. C. et al. Estrogen receptors α and β as determinants of gene expression: influence of ligand, dose, and chromatin binding. Mol. Endocrinol. 22, 1032-1043 (2008). (Pubitemid 351629605)
68. Williams, C., Edvardsson, K., Lewandowski, S. A., Strom, A. & Gustafsson, J. A genome-wide study of the repressive effects of estrogen receptor β on estrogen receptor α signaling in breast cancer cells. Oncogene 27, 1019-1032 (2008). (Pubitemid 351225390)
69. Lindberg, K., Helguero, L. A., Omoto, Y., Gustafsson, J., & Haldosen, L. A. Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN-implications for tamoxifen sensitivity. Breast Cancer Res. 13, R43 (2011).
70. Paruthiyil, S. et al. Estrogen receptor β causes a G2 cell cycle arrest by inhibiting CDK1 activity through the regulation of cyclin B1, GADD45A, and BTG2. Breast Cancer Res. Treat. 1 Dec 2010 (doi:10.1007/s10549-010-1273-5).
71. Cvoro, A. et al. Selective activation of estrogen receptor-β transcriptional pathways by an herbal extract. Endocrinology 148, 538-547 (2007). (Pubitemid 46150775)
72. Hartman, J. et al. Estrogen receptor β inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res. 66, 11207-11213 (2006). (Pubitemid 46009948)
73. Mersereau, J. E. et al. Liquiritigenin is a plant-derived highly selective estrogen receptor β agonist. Mol. Cell. Endocrinol. 283, 49-57 (2008).
74. Ellem, S. J. & Risbridger, G. P. Aromatase and regulating the estrogen:androgen ratio in the prostate gland. J. Steroid Biochem. Mol. Biol. 118, 246-251 (2010).
75. McPherson, S. J. et al. Essential role for estrogen receptor β in stromal-epithelial regulation of prostatic hyperplasia. Endocrinology 148, 566-574 (2007). (Pubitemid 46143161)
76. McPherson, S. J. et al. Estrogen receptor-β activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFα mediated. Proc. Natl Acad. Sci. USA 107, 3123-3128 (2010).
77. Kennelly, R., Kavanagh, D. O., Hogan, A. M. & Winter, D. C. Oestrogen and the colon: potential mechanisms for cancer prevention. Lancet Oncol. 9, 385-391 (2008). (Pubitemid 351411655)
78. Long, M. D., Martin, C. F., Galanko, J. A. & Sandler, R. S. Hormone replacement therapy, oral contraceptive use, and distal large bowel cancer: a population-based case-control study. Am. J. Gastroenterol. 105, 1843-1850 (2010).
79. Wada-Hiraike, O. et al. Role of estrogen receptor β in colonic epithelium. Proc. Natl Acad. Sci. USA 103, 2959-2964 (2006).
80. Hartman, J. et al. Tumor repressive functions of estrogen receptor β in SW480 colon cancer cells. Cancer Res. 69, 6100-6106 (2009).
81. Weige, C. C., Allred, K. F. & Allred, C. D. Estradiol alters cell growth in nonmalignant colonocytes and reduces the formation of preneoplastic lesions in the colon. Cancer Res. 69, 9118-9124 (2009).
82. Pinton, G. et al. Estrogen receptor-β affects the prognosis of human malignant mesothelioma. Cancer Res. 69, 4598-4604 (2009).
83. Pinton, G. et al. Estrogen receptor β exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib. PLoS ONE 5, e14110 (2010).
84. Yakimchuk, K. et al. Effect of ligand-activated estrogen receptor β on lymphoma growth in vitro and in vivo. Leukemia 25, 1103-1110 (2011).
85. Yamasaki, M. et al. Genistein induced apoptotic cell death in adult T-cell leukemia cells through estrogen receptors. Biosci. Biotechnol. Biochem. 74, 2113-2115 (2010).
86. Arias-Loza, P. A., Jazbutyte, V. & Pelzer, T. Genetic and pharmacologic strategies to determine the function of estrogen receptor α and estrogen receptor β in cardiovascular system. Gend. Med. 5 (Suppl. A), 34-45 (2008).
87. Vitale, C., Mendelsohn, M. E. & Rosano, G. M. Gender differences in the cardiovascular effect of sex hormones. Nature Rev. Cardiol. 6, 532-542 (2009).
88. Guo, X., Razandi, M., Pedram, A., Kassab, G. & Levin, E. R. Estrogen induces vascular wall dilation: mediation through kinase signaling to nitric oxide and estrogen receptors α and β. J. Biol. Chem. 280, 19704-19710 (2005). (Pubitemid 41379495)
89. Zhu, Y. et al. Abnormal vascular function and hypertension in mice deficient in estrogen receptor β. Science 295, 505-508 (2002). (Pubitemid 34101642)
90. Arias-Loza, P. A. et al. Both estrogen receptor subtypes, α and β, attenuate cardiovascular remodeling in aldosterone salt-treated rats. Hypertension 50, 432-438 (2007).
91. Jazbutyte, V. et al. Ligand-dependent activation of ERβ lowers blood pressure and attenuates cardiac hypertrophy in ovariectomized spontaneously hypertensive rats. Cardiovasc. Res. 77, 774-781 (2008). (Pubitemid 351301861)
92. Fliegner, D. et al. Female sex and estrogen receptor-β attenuate cardiac remodeling and apoptosis in pressure overload. Am. J. Physiol. Regul. Integr. Comp. Physiol. 298, R1597-R1606 (2010).
93. Kararigas, G., Fliegner, D., Gustafsson, J. & Regitz-Zagrosek, V. The role of the estrogen/estrogen-receptor-β axis in the genomic response to pressure overload-induced hypertrophy. Physiol. Genomics 43, 438-446 (2011).
94. Pedram, A., Razandi, M., O'Mahony, F., Lubahn, D. & Levin, E. R. Estrogen receptor-β prevents cardiac fibrosis. Mol. Endocrinol. 24, 2152-2165 (2010).
95. Pelzer, T. et al. Increased mortality and aggravation of heart failure in estrogen receptor-β knockout mice after myocardial infarction. Circulation 111, 1492-1498 (2005). (Pubitemid 40470643)
96. Skavdahl, M. et al. Estrogen receptor-β mediates male-female differences in the development of pressure overload hypertrophy. Am. J. Physiol. Heart Circ. Physiol. 288, H469-H476 (2005). (Pubitemid 40139627)
97. Nikolic, I. et al. Treatment with an estrogen receptor-β-selective agonist is cardioprotective. J. Mol. Cell. Cardiol. 42, 769-780 (2007). (Pubitemid 46527602)
98. Hodgin, J. B. et al. Estrogen receptor α is a major mediator of 17β-estradiol's atheroprotective effects on lesion size in Apoe-/-mice. J. Clin. Invest. 107, 333-340 (2001). (Pubitemid 32157965)
99. Villablanca, A. C. et al. 17β-estradiol prevents early-stage atherosclerosis in estrogen receptor-α deficient female mice. J. Cardiovasc. Transl. Res. 2, 289-299 (2009).
100. Pockley, A. G., Georgiades, A., Thulin, T., de Faire, U. & Frostegard, J. Serum heat shock protein 70 levels predict the development of atherosclerosis in subjects with established hypertension. Hypertension 42, 235-238 (2003). (Pubitemid 37093466)
101. Zhu, J. et al. Increased serum levels of heat shock protein 70 are associated with low risk of coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 23, 1055-1059 (2003). (Pubitemid 36713560)
102. Martin-Ventura, J. L. et al. Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis. Circulation 110, 2216-2219 (2004). (Pubitemid 39372504)
103. Rayner, K. et al. Heat shock protein 27 protects against atherogenesis via an estrogen-dependent mechanism: role of selective estrogen receptor β modulation. Arterioscler. Thromb. Vasc. Biol. 29, 1751-1756 (2009).
104. Rayner, K. et al. Extracellular release of the atheroprotective heat shock protein 27 is mediated by estrogen and competitively inhibits acLDL binding to scavenger receptor-A. Circ. Res. 103, 133-141 (2008).
105. Sun, J. et al. Attenuation of atherogenesis via the anti-inflammatory effects of the selective estrogen receptor β modulator 8β-VE2. J. Cardiovasc. Pharmacol. 18 Jun 2011 (doi:10.1097/FJC.0b013e318226bd16).
106. Gold, S. M. & Voskuhl, R. R. Estrogen and testosterone therapies in multiple sclerosis. Prog. Brain Res. 175, 239-251 (2009).
107. Soldan, S. S., Alvarez Retuerto, A. I., Sicotte, N. L. & Voskuhl, R. R. Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol. J. Immunol. 171, 6267-6274 (2003). (Pubitemid 37467250)
108. Compston, A. & Coles, A. Multiple sclerosis. Lancet 359, 1221-1231 (2002). (Pubitemid 34304266)
109. Bodhankar, S., Wang, C., Vandenbark, A. A. & Offner, H. Estrogen-induced protection against experimental autoimmune encephalomyelitis is abrogated in the absence of B cells. Eur. J. Immunol. 41, 1165-1175 (2011).
110. Crawford, D. K. et al. Oestrogen receptor β ligand: a novel treatment to enhance endogenous functional remyelination. Brain 133, 2999-3016 (2010).
111. Palaszynski, K. M., Liu, H., Loo, K. K. & Voskuhl, R. R. Estriol treatment ameliorates disease in males with experimental autoimmune encephalomyelitis: implications for multiple sclerosis. J. Neuroimmunol. 149, 84-89 (2004). (Pubitemid 38352861)
112. Sicotte, N. L. et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann. Neurol. 52, 421-428 (2002).
113. Elloso, M. M., Phiel, K., Henderson, R. A., Harris, H. A. & Adelman, S. J. Suppression of experimental autoimmune encephalomyelitis using estrogen receptor-selective ligands. J. Endocrinol. 185, 243-252 (2005). (Pubitemid 40691791)
114. Polanczyk, M. et al. Estrogen receptor-1 (Esr1) and-2 (Esr2) regulate the severity of clinical experimental allergic encephalomyelitis in male mice. Am. J. Pathol. 164, 1915-1924 (2004). (Pubitemid 38669341)
115. Polanczyk, M. et al. The protective effect of 17β-estradiol on experimental autoimmune encephalomyelitis is mediated through estrogen receptor-α. Am. J. Pathol. 163, 1599-1605 (2003). (Pubitemid 37175106)
116. Tiwari-Woodruff, S., Morales, L. B., Lee, R. & Voskuhl, R. R. Differential neuroprotective and antiinflammatory effects of estrogen receptor (ER)α and ERβ ligand treatment. Proc. Natl Acad. Sci. USA 104, 14813-14818 (2007). (Pubitemid 350003225)
117. Du, S., Sandoval, F., Trinh, P. & Voskuhl, R. R. Additive effects of combination treatment with anti-inflammatory and neuroprotective agents in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 219, 64-74 (2010).
118. De Angelis, M., Stossi, F., Carlson, K. A., Katzenellenbogen, B. S. & Katzenellenbogen, J. A. Indazole estrogens: highly selective ligands for the estrogen receptor β. J. Med. Chem. 48, 1132-1144 (2005). (Pubitemid 40270455)
119. Selkoe, D. J. & Schenk, D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu. Rev. Pharmacol. Toxicol. 43, 545-584 (2003). (Pubitemid 37372653)
120. Vegeto, E., Benedusi, V. & Maggi, A. Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases. Front. Neuroendocrinol. 29, 507-519 (2008).
121. Pike, C. J., Carroll, J. C., Rosario, E. R. & Barron, A. M. Protective actions of sex steroid hormones in Alzheimer's disease. Front. Neuroendocrinol. 30, 239-258 (2009).
122. Yue, X. et al. Brain estrogen deficiency accelerates Aβ plaque formation in an Alzheimer's disease animal model. Proc. Natl Acad. Sci. USA 102, 19198-19203 (2005). (Pubitemid 43049589)
123. Shumaker, S. A. et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291, 2947-2958 (2004). (Pubitemid 38802684)
124. Brinton, R. D. Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action. Ann. N. Y. Acad. Sci. 1052, 57-74 (2005). (Pubitemid 41338958)
125. Leissring, M. A. et al. Enhanced proteolysis of β-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40, 1087-1093 (2003). (Pubitemid 38032786)
126. Liang, K. et al. Estrogen stimulates degradation of β-amyloid peptide by up-regulating neprilysin. J. Biol. Chem. 285, 935-942 (2010).
127. Zhao, L. et al. 17β-Estradiol regulates insulin-degrading enzyme expression via an ERβ/PI3-K pathway in hippocampus: relevance to Alzheimer's prevention. Neurobiol. Aging 6 Jan 2010 (doi:10.1016/j. neurobiolaging.2009.12.010).
128. Grady, D. et al. MF101, a selective estrogen receptor β modulator for the treatment of menopausal hot flushes: a phase II clinical trial. Menopause 16, 458-465 (2009).
129. Zhao, L., Mao, Z. & Brinton, R. D. A select combination of clinically relevant phytoestrogens enhances estrogen receptor β-binding selectivity and neuroprotective activities in vitro and in vivo. Endocrinology 150, 770-783 (2009).
130. Jordan, V. C. Selective estrogen receptor modulation: a personal perspective. Cancer Res. 61, 5683-5687 (2001). (Pubitemid 32769076)
131. Grigsby, J. G. et al. Effects of tamoxifen versus raloxifene on retinal capillary endothelial cell proliferation. J. Ocul. Pharmacol. Ther. 27, 225-233 (2011).
132. Albertazzi, P. & Sharma, S. Urogenital effects of selective estrogen receptor modulators: a systematic review. Climacteric 8, 214-220 (2005). (Pubitemid 41224434)
133. Hendrix, S. L. & McNeeley, S. G. Effect of selective estrogen receptor modulators on reproductive tissues other than endometrium. Ann. N. Y. Acad. Sci. 949, 243-250 (2001). (Pubitemid 34059986)
134. McDonnell, D. P., Clemm, D. L., Hermann, T., Goldman, M. E. & Pike, J. W. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol. Endocrinol. 9, 659-669 (1995).
135. Shang, Y. & Brown, M. Molecular determinants for the tissue specificity of SERMs. Science 295, 2465-2468 (2002). (Pubitemid 34270263)
136. Tzukerman, M. T. et al. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol. Endocrinol. 8, 21-30 (1994). (Pubitemid 24034253)
137. Shelly, W., Draper, M. W., Krishnan, V., Wong, M. & Jaffe, R. B. Selective estrogen receptor modulators: an update on recent clinical findings. Obstet. Gynecol. Surv. 63, 163-181 (2008). (Pubitemid 351612435)
138. Barkhem, T. et al. Differential response of estrogen receptor α and estrogen receptor β to partial estrogen agonists/antagonists. Mol. Pharmacol. 54, 105-112 (1998). (Pubitemid 28337592)
139. Schechter, I. & Berger, A. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 27, 157-162 (1967).